

Fax completed form to: 1-866-868-0858  
Questions, please call: 1-866-316-6049



## **Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Intron A® (interferon alpha 2-b): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Intron A® (interferon alpha 2-b) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

### Information about this drug

---

#### Intron A® (interferon alpha 2-b)

Interferons should be used cautiously in patients with bone marrow depression, severe cardiac disease or diabetes, renal or pulmonary disease, infectious, neuropsychiatric conditions or renal dysfunction. Intron A® should be administered cautiously in the elderly population. Post marketing surveillance revealed a greater incidence of adverse effects in the elderly compared with younger patients.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

# Prior Authorization Request Form



Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
 Member ID \_\_\_\_\_  
 Medicare ID \_\_\_\_\_  
 Date of birth \_\_\_\_\_ Sex: M / F  
 Address \_\_\_\_\_  
 City \_\_\_\_\_  
 State \_\_\_\_\_ ZIP \_\_\_\_\_  
 Phone \_\_\_\_\_  
 Nursing home resident? YES / NO  
 Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
 Specialty \_\_\_\_\_  
 DEA \_\_\_\_\_  
 NPI \_\_\_\_\_  
 Address \_\_\_\_\_  
 City \_\_\_\_\_  
 State \_\_\_\_\_ ZIP \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_  
 Pharmacy name \_\_\_\_\_  
 NCPDP \_\_\_\_\_  
 NPI \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
 Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Intron A® (interferon alpha 2-b) Criteria

- 1 Please indicate Intron-A®'s dispensing location:
  - Pharmacy
  - Physician's supply, incident to a physician's service
  - Other: \_\_\_\_\_
- 2 Please indicate the patient's diagnosis. Select or specify the correct ICD-9 code. This question must be completed.
  - AIDS-related Kaposi's sarcoma, (>=18 years)(ICD-9: 176)
  - Condyloma acuminatum in patients, (>=18 years) unresponsive to podophyllin regimens, when external surfaces of the genital and perianal areas are involved (ICD-9: 078.11)
  - Follicular lymphoma: Initial treatment in conjunction with anthracycline-containing combination chemotherapy, (>=18 years)(ICD-9: 202)
  - Hairy cell leukemia, (>=18 years)(ICD-9: 202.4)
  - Hepatitis C, chronic, (>=18 years of age) with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive (ICD-9: 070)
  - Malignant melanoma, (>=18 years)adjuvant therapy for high risk patients (ICD-9: 172)
  - Chronic hepatitis B, (>=1 year of age) who have compensated liver disease and evidence of viral replication (detectable levels of HBV DNA) and liver inflammation (ALT> 2xULN)(ICD-9: 070)
- 3 Does the patient have a history of hypersensitivity to interferons?
  - Yes  No
- 4 Is the prescribing physician an oncologist, gastroenterologist or dermatologist?
  - Yes  No

Medical justification: (Attach additional page if necessary): \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_